Aldosterone antagonism and congestive heart failure: A new look at an old therapy Article Report uri icon


MeSH Major

  • Heart Failure
  • Inflammation Mediators
  • Interleukin-6
  • Tumor Necrosis Factor-alpha


  • Combined clinical and detailed mechanistic investigations have established mineralocorticoid receptor antagonism as the new treatment paradigm for congestive heart failure. Recent clinical data have demonstrated that treatment of patients with a combination of mineralocorticoid receptor antagonism (eplerenone) and angiotensin converting enzyme-inhibitor (ACE-I) results in substantial reduction in left ventricular mass. Furthermore, a federally funded initiative to treat more than 6000 patients with diastolic heart failure with spironolactone is in its final phases of planning. It is foreseeable that, along with ACE-I and beta-blockers, mineralocorticoid receptor antagonism will become part of the treatment paradigm for people across the entire spectrum of cardiovascular disease.

publication date

  • July 2004



  • Report


Digital Object Identifier (DOI)

  • 10.1097/01.hco.0000129667.34622.14

PubMed ID

  • 15218387

Additional Document Info

start page

  • 301

end page

  • 8


  • 19


  • 4